Holen Sie sich die Stockscreener-App
319.41
1.27%
-3.99
Schlusskurs vom Vortag:
$323.40
Offen:
$326.35
24-Stunden-Volumen:
542.70K
Relative Volume:
0.88
Marktkapitalisierung:
$22.47B
Einnahmen:
$2.36B
Nettoeinkommen (Verlust:
$236.10M
KGV:
97.20
EPS:
3.286
Netto-Cashflow:
$382.50M
1W Leistung:
+2.01%
1M Leistung:
+1.86%
6M Leistung:
+20.80%
1J Leistung:
+30.33%
1-Tages-Spanne:
$316.86
$332.95
1-Wochen-Bereich:
$290.16
$335.00
52-Wochen-Spanne:
$230.05
$353.50
Insulet Corporation Stock (PODD) Company Profile
Firmenname
Insulet Corporation
Sektor
Branche
Telefon
978-600-7000
Adresse
100 NAGOG PARK, ACTON, MA
Vergleichen Sie PODD mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
PODD
Insulet Corporation
|
319.28 | 22.76B | 2.36B | 236.10M | 382.50M | 3.286 |
|
ABT
Abbott Laboratories
|
126.19 | 217.27B | 43.84B | 13.90B | 6.92B | 7.9725 |
|
BSX
Boston Scientific Corp
|
100.00 | 146.84B | 19.35B | 2.78B | 3.82B | 1.8696 |
|
SYK
Stryker Corp
|
356.03 | 135.31B | 24.38B | 2.94B | 4.07B | 7.6159 |
|
MDT
Medtronic Plc
|
92.08 | 115.51B | 34.20B | 4.69B | 5.30B | 3.6218 |
|
EW
Edwards Lifesciences Corp
|
83.27 | 47.84B | 5.88B | 1.34B | 577.90M | 2.3455 |
Insulet Corporation Stock (PODD) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-10-21 | Fortgesetzt | Stifel | Buy |
| 2025-09-08 | Fortgesetzt | Oppenheimer | Outperform |
| 2025-06-16 | Eingeleitet | Truist | Buy |
| 2025-05-30 | Eingeleitet | Goldman | Buy |
| 2025-05-13 | Hochstufung | Wolfe Research | Peer Perform → Outperform |
| 2025-04-29 | Herabstufung | Wolfe Research | Outperform → Peer Perform |
| 2025-03-06 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2024-11-06 | Eingeleitet | Bernstein | Outperform |
| 2024-05-30 | Eingeleitet | Redburn Atlantic | Buy |
| 2024-05-07 | Hochstufung | Wolfe Research | Peer Perform → Outperform |
| 2023-12-21 | Hochstufung | Robert W. Baird | Neutral → Outperform |
| 2023-12-04 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2023-10-02 | Hochstufung | Jefferies | Hold → Buy |
| 2023-08-21 | Hochstufung | Citigroup | Neutral → Buy |
| 2023-08-21 | Herabstufung | Robert W. Baird | Outperform → Neutral |
| 2023-05-30 | Fortgesetzt | Morgan Stanley | Equal-Weight |
| 2023-01-26 | Eingeleitet | Wolfe Research | Peer Perform |
| 2022-11-04 | Hochstufung | Piper Sandler | Neutral → Overweight |
| 2022-10-18 | Eingeleitet | Barclays | Equal Weight |
| 2022-10-12 | Eingeleitet | Jefferies | Hold |
| 2022-07-11 | Herabstufung | Citigroup | Buy → Neutral |
| 2022-03-02 | Fortgesetzt | BofA Securities | Buy |
| 2022-02-03 | Hochstufung | BTIG Research | Neutral → Buy |
| 2022-02-02 | Hochstufung | UBS | Neutral → Buy |
| 2022-01-31 | Hochstufung | Oppenheimer | Perform → Outperform |
| 2021-07-21 | Fortgesetzt | Cowen | Outperform |
| 2021-05-25 | Eingeleitet | Barclays | Overweight |
| 2021-04-01 | Hochstufung | SVB Leerink | Mkt Perform → Outperform |
| 2021-03-19 | Hochstufung | Canaccord Genuity | Hold → Buy |
| 2021-01-29 | Herabstufung | Piper Sandler | Overweight → Neutral |
| 2020-12-16 | Herabstufung | Citigroup | Buy → Neutral |
| 2020-07-28 | Eingeleitet | Wells Fargo | Overweight |
| 2020-04-24 | Herabstufung | SVB Leerink | Outperform → Mkt Perform |
| 2020-04-03 | Eingeleitet | BofA/Merrill | Neutral |
| 2020-03-31 | Herabstufung | Berenberg | Buy → Hold |
| 2020-03-05 | Eingeleitet | Citigroup | Buy |
| 2019-12-10 | Eingeleitet | CFRA | Sell |
| 2019-10-23 | Eingeleitet | Stifel | Hold |
| 2019-10-18 | Herabstufung | Canaccord Genuity | Buy → Hold |
| 2019-10-14 | Herabstufung | BTIG Research | Buy → Neutral |
| 2019-10-04 | Herabstufung | UBS | Buy → Neutral |
| 2019-10-03 | Herabstufung | Guggenheim | Buy → Neutral |
| 2019-08-06 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2019-06-10 | Herabstufung | Northland Capital | Outperform → Market Perform |
| 2019-05-06 | Hochstufung | BTIG Research | Neutral → Buy |
| 2018-04-20 | Eingeleitet | Berenberg | Buy |
| 2018-02-22 | Bestätigt | Barclays | Overweight |
| 2018-01-08 | Hochstufung | Raymond James | Mkt Perform → Outperform |
| 2017-11-03 | Hochstufung | Canaccord Genuity | Hold → Buy |
| 2017-09-15 | Eingeleitet | Barclays | Overweight |
Alle ansehen
Insulet Corporation Aktie (PODD) Neueste Nachrichten
Wells Fargo Raises Price Target for Insulet (PODD) to $360 | POD - GuruFocus
PODD: RBC Capital Raises Price Target for Insulet to $370, Maint - GuruFocus
UBS Maintains Neutral Rating on PODD, Raises Price Target | PODD Stock News - GuruFocus
3 Reasons Why Growth Investors Shouldn't Overlook Insulet (PODD) - sharewise.com
Bernstein Adjusts Insulet Price Target to $410 From $400 - MarketScreener
Did Insulet's (PODD) Upbeat Quarter and Raised Outlook Just Shift Its Investment Narrative? - Yahoo Finance
RBC Adjusts Price Target on Insulet to $370 From $365, Maintains Outperform Rating - MarketScreener
UBS Adjusts Price Target on Insulet to $355 From $320, Maintains Neutral Rating - MarketScreener
Barclays Raises Price Target for Insulet (PODD) to $316 | PODD S - GuruFocus
Insulet Corporation (NASDAQ:PODD) Q3 2025 Earnings Call Transcript - Insider Monkey
Wolfe Research Adjusts Price Target on Insulet to $375 From $350, Maintains Outperform Rating - MarketScreener
Leerink Partners Adjusts Price Target on Insulet to $385 From $355, Maintains Outperform Rating - MarketScreener
Goldman Sachs Adjusts Price Target on Insulet to $388 From $375, Maintains Buy Rating - MarketScreener
Rothschild & Co Redburn Adjusts Price Target on Insulet to $380 From $370, Maintains Buy Rating - MarketScreener
Jefferies Adjusts Price Target on Insulet to $400 From $375, Maintains Buy Rating - MarketScreener
Canaccord Genuity Adjusts Price Target on Insulet to $428 From $399, Maintains Buy Rating - MarketScreener
Wells Fargo Adjusts Price Target on Insulet to $360 From $350, Maintains Overweight Rating - MarketScreener
Why Insulet Corporation (GOV) stock stays resilientBear Alert & Low Risk High Win Rate Stock Picks - newser.com
Is Insulet Corporation stock poised for growth2025 AllTime Highs & Consistent Return Investment Signals - newser.com
How institutional ownership impacts Insulet Corporation stockJuly 2025 Price Swings & Advanced Technical Analysis Signals - newser.com
How Insulet’s (PODD) Raised Outlook and Surging Omnipod Demand Will Impact Investors - simplywall.st
Chart based exit strategy for Insulet CorporationMarket Activity Summary & Expert Verified Stock Movement Alerts - newser.com
Insulet’s (NASDAQ:PODD) Q3: Strong Sales - The Globe and Mail
Insulet Corporation Reports Strong Q3 2025 Results - TipRanks
Will Insulet Corporation rebound enough to break evenRecession Risk & Weekly Chart Analysis and Guides - newser.com
Insulet raises full-year Omnipod revenue growth guidance to 29–30% as international momentum accelerates - MSN
Insulet Corp. Reveals Advance In Q3 Income - Nasdaq
Jefferies raises Insulet stock price target to $400 on strong sales growth - Investing.com Australia
Insulet: Q3 Earnings Snapshot - Stamford Advocate
PODD: Jefferies Raises Price Target to $400 on Insulet | PODD St - GuruFocus
BTIG reiterates Buy rating on Insulet stock after strong Q3 results - Investing.com Canada
Insulet Corporation (PODD) PT Raised to $400 at Jefferies - StreetInsider
Insulet leadership talks patch pump competition, expanding type 2 diabetes market - MassDevice
BTIG Reiterates Buy Rating on Insulet Corporation (PODD) - StreetInsider
Will Insulet Corporation stock recover after recent dropEarnings Overview Summary & Smart Money Movement Alerts - newser.com
Why Insulet Corporation (GOV) stock could break out in 2025Trade Risk Assessment & Consistent Income Trade Recommendations - newser.com
Insulet’s Wearable Insulin Pumps Deliver Strong Results In 2025 - Finimize
Insulet Delivers Big Growth And Raises Guidance For 2025 - Finimize
Insulet Q3 2025 slides: revenue surges 30%, guidance raised amid international expansion - Investing.com
Why Insulet Corporation stock is rated strong buyPortfolio Performance Report & Accurate Buy Signal Alerts - newser.com
Earnings call transcript: Insulet beats Q3 2025 forecasts, stock rises By Investing.com - Investing.com Canada
Earnings call transcript: Insulet beats Q3 2025 forecasts, stock rises - Investing.com India
Insulet Corporation Provides Revenue Guidance for the Fourth Quarter and Full Year Ending December 31, 2025 - MarketScreener
Insulet (PODD) Q3 Earnings and Revenues Beat Estimates - sharewise.com
Insulet (PODD) Reports Q3 Earnings: What Key Metrics Have to Say - Yahoo Finance
Insulet Corporation Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2025 - MarketScreener
Insulet : Q3 2025 Insulet Corporation Earnings Call - MarketScreener
Insulet (PODD) Projects Revenue Growth for FY25 - GuruFocus
Insulet (PODD) Forecasts Strong Revenue Growth for Q4 - GuruFocus
PODD Sees Strong Q3 Revenue Boost Exceeding Expectations - GuruFocus
Insulet Corp (PODD) Q3 2025 Earnings: EPS of $1.24 Beats Estimat - GuruFocus
Finanzdaten der Insulet Corporation-Aktie (PODD)
Umsatz
Nettogewinn
Free Cashflow
ENV
Insulet Corporation-Aktie (PODD) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Singh Prem | SVP, Global Operations |
Sep 08 '25 |
Sale |
347.49 |
687 |
238,726 |
3,456 |
| Cousin Laetitia | SVP, Reg, Quality & Compliance |
Sep 08 '25 |
Option Exercise |
241.10 |
797 |
192,160 |
4,687 |
| Cousin Laetitia | SVP, Reg, Quality & Compliance |
Sep 08 '25 |
Sale |
348.81 |
797 |
278,002 |
3,890 |
5.64%
1.08%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):